Blocking MDM2 Could Be The Key To Stopping Some Pediatric Sarcomas

Pediatric sarcomas are notoriously difficult to treat because they lack precise, molecularly targeted therapies. In this study, scientists discovered that a protein called MDM2 acts as a major fuel source for these tumors. MDM2 drives cancer growth through two distinct mechanisms: first, by destroying p53 (a natural “tumor-suppressor” protein that normally forces damaged cells to die), and second, by directly binding to the cell’s DNA to supercharge the production of cancer-promoting genes. Because the cancer cells become completely addicted to this process, the researchers realized that blocking MDM2 could be the key to stopping the tumor.

To exploit this vulnerability, the researchers created a new class of drugs called MDM2-TEMADs featuring a lead compound named dCDK9-010. This drug acts like a smart molecular crowbar. It hijacks the cancer cell’s own overabundant MDM2 protein and forces it to destroy CDK9, a vital engine the cell uses to read its DNA. By wiping out CDK9 the drug simultaneously forces the tumor to stop producing cancer genes, reactivates the p53 tumor-suppressor, and damages the cancer’s ability to repair its own DNA. In animal and laboratory testing this treatment vigorously shrank tumors while completely sparing healthy cells thus offering a promising, highly selective new strategy for treating pediatric sarcomas.

Read the full article